Resmed (RMD) Accumulated Expenses (2010 - 2026)

Resmed (RMD) has 17 years of Accumulated Expenses data on file, last reported at $446.1 million in Q1 2026.

• Quarterly Accumulated Expenses rose 15.49% year-over-year to $446.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $446.1 million (up 15.49% YoY) and the FY2025 annual result came in at $402.3 million, up 6.51% from the prior year.
• Accumulated Expenses grew to $446.1 million in Q1 2026, from $391.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $446.1 million in Q1 2026 to a low of $312.2 million in Q4 2022.
• A 5-year average of $363.2 million and a median of $356.1 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses advanced 18.22% — and 2024, when it increased 2.51%.
• Tracing RMD's Accumulated Expenses over 5 years: stood at $312.2 million in 2022, then rose by 6.4% to $332.1 million in 2023, then climbed by 6.14% to $352.5 million in 2024, then rose by 11.05% to $391.5 million in 2025, then advanced by 13.96% to $446.1 million in 2026.
• The last three Accumulated Expenses figures came in at $446.1 million (Q1 2026), $391.5 million (Q4 2025), and $395.8 million (Q3 2025), per Business Quant data.